132 related articles for article (PubMed ID: 7696824)
1. Effect of tibolone on postmenopausal bone loss.
Rymer J; Chapman MG; Fogelman I
Osteoporos Int; 1994 Nov; 4(6):314-9. PubMed ID: 7696824
[TBL] [Abstract][Full Text] [Related]
2. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss.
Rymer J; Robinson J; Fogelman I
Osteoporos Int; 2001; 12(6):478-83. PubMed ID: 11446564
[TBL] [Abstract][Full Text] [Related]
3. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.
Thiébaud D; Bigler JM; Renteria S; Pache T; Welti HJ; Landry M; Burckhardt P
Climacteric; 1998 Sep; 1(3):202-10. PubMed ID: 11907945
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures.
Studd J; Arnala I; Kicovic PM; Zamblera D; Kröger H; Holland N
Obstet Gynecol; 1998 Oct; 92(4 Pt 1):574-9. PubMed ID: 9764631
[TBL] [Abstract][Full Text] [Related]
5. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures.
Pavlov PW; Ginsburg J; Kicovic PM; van der Schaaf DB; Prelevic G; Bennink HJ
Gynecol Endocrinol; 1999 Aug; 13(4):230-7. PubMed ID: 10533157
[TBL] [Abstract][Full Text] [Related]
6. Association of tibolone and fluoride displays a pronounced effect on bone mineral density in postmenopausal osteoporotic women.
Reginster JY; Agnusdei D; Gennari C; Kicovic PM
Gynecol Endocrinol; 1999 Oct; 13(5):361-8. PubMed ID: 10599554
[TBL] [Abstract][Full Text] [Related]
7. Tibolone and osteoporosis.
Lazovic G; Radivojevic U; Milosevic V; Lazovic A; Jeremic K; Glisic A
Arch Gynecol Obstet; 2007 Dec; 276(6):577-81. PubMed ID: 17605023
[TBL] [Abstract][Full Text] [Related]
8. A longitudinal evaluation of the effect of two doses of tibolone on bone density and metabolism in early postmenopausal women.
Gambacciani M; Ciaponi M; Cappagli B; Monteleone P; Benussi C; Bevilacqua G; Genazzani AR
Gynecol Endocrinol; 2004 Jan; 18(1):9-16. PubMed ID: 15106359
[TBL] [Abstract][Full Text] [Related]
9. Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis.
Parviainen MT; Jääskeläinen K; Kröger H; Arnala I; Alhava E
Clin Chim Acta; 1999 Jan; 279(1-2):145-54. PubMed ID: 10064126
[TBL] [Abstract][Full Text] [Related]
10. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P
J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
[TBL] [Abstract][Full Text] [Related]
11. The effect of tibolone on bone mineral density in postmenopausal women with osteopenia or osteoporosis--8 years follow-up.
Prelevic GM; Markou A; Arnold A; Bartram C; Puzigaca Z; Ginsburg J
Maturitas; 2004 Mar; 47(3):229-34. PubMed ID: 15036493
[TBL] [Abstract][Full Text] [Related]
12. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
13. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women.
Rymer J; Robinson J; Fogelman I
Climacteric; 2002 Dec; 5(4):390-8. PubMed ID: 12626219
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women.
Yang TS; Tsan SH; Chen CR; Chang SP; Yuan CC
Zhonghua Yi Xue Za Zhi (Taipei); 1999 May; 62(5):308-15. PubMed ID: 10389286
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of the effectiveness of 17-beta-estradiol and calcitonin in women with postmenopausal bone loss].
Stĕpán J; Formánková J; Masatová A; Michalský M; Rosenová Z
Cas Lek Cesk; 1997 Apr; 136(8):242-8. PubMed ID: 9264868
[TBL] [Abstract][Full Text] [Related]
16. Prevention of post-oophorectomy bone loss with Tibolone.
Lyritis GP; Karpathios S; Basdekis K; Grigoriou O; Katostaras T; Paspati I; Stamatopoulos T; Siampalioti G; Lyritis PG
Maturitas; 1995 Nov; 22(3):247-53. PubMed ID: 8746883
[TBL] [Abstract][Full Text] [Related]
17. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial.
Beardsworth SA; Kearney CE; Purdie DW
Br J Obstet Gynaecol; 1999 Jul; 106(7):678-83. PubMed ID: 10428524
[TBL] [Abstract][Full Text] [Related]
18. Effect of misoprostol on bone mineral density in women with postmenopausal osteoporosis.
Yasar L; Sönmez AS; Utku N; Ozcan J; Cebi Z; Savan K; Sut N; Yazicioğlu F
Prostaglandins Other Lipid Mediat; 2006 May; 79(3-4):199-205. PubMed ID: 16647634
[TBL] [Abstract][Full Text] [Related]
19. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies.
Gallagher JC; Baylink DJ; Freeman R; McClung M
J Clin Endocrinol Metab; 2001 Oct; 86(10):4717-26. PubMed ID: 11600531
[TBL] [Abstract][Full Text] [Related]
20. Rates of bone loss in peri- and postmenopausal women: a 4 year, prospective, population-based study.
Young R; May H; Murphy S; Grey C; Compston JE
Clin Sci (Lond); 1996 Sep; 91(3):307-12. PubMed ID: 8869413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
